*This report is informational only and not medical advice.* epocrates is a clinical decision support platform for U.S. healthcare professionals, providing drug references, interaction checkers, and pill identification. While it is the #1 Grossing app in its category, it is currently facing a decline in user trust due to aggressive monetization and critical stability issues.
The App DNA
What makes this app unique?
For U.S.-based healthcare professionals including physicians (MDs/DOs), nurse practitioners, physician associates, pharmacists, and medical students.
What does it look like?
Key features
Simultaneously check interactions for up to 30 medications
Visual tool to identify pills by imprint, shape, color, or image
Full functionality available without internet connectivity
How much does it cost?
The app has recently moved toward aggressive gating of core drug data, limiting free users to as few as 1-2 views per week, which is driving significant negative sentiment among long-term professional users.
Velocity
Maintenance developmentperformanceShow more...
The development team is currently focused exclusively on maintenance, with no major feature releases identified in the observed data. The cadence consists solely of minor stability patches across iOS and Android platforms. There is no evidence of new feature development or significant product evolution in the recent release cycle.
Who built it?
User Sentiment
What do users think recently?
Recent user voice shows a frustrated sentiment. Users appreciate clinical utility, but report aggressive monetization.
How are ratings & reviews evolving?
What users say, by theme
- Clinical Utility
Unlock 1 more frustration theme, each backed by review evidence.
Access the full report for freeCompetition
Competitive landscape for epocrates: Drug Info & Pill ID
How's the Medical market?
The rivals identified
By MD Aware, LLC
Both apps target the same U.S. healthcare professional audience for bedside clinical decision support, creating direct competition for daily clinical workflow time.
- MDCalc provides 900+ evidence-based clinical calculators, whereas epocrates focuses on drug references and pill identification.
- MDCalc offers free access to its entire library, while epocrates gates core drug data behind a premium paywall.
- MDCalc includes integrated CME tracking, a feature currently absent from the epocrates clinical toolset.
Unlock the head-to-head verdict: where this rival wins, and where it loses.
Access the full report for freeThe Analyst's Read
Key takeaways for epocrates: Drug Info & Pill ID
Where is it heading?
- v26.4.0 update causing immediate crashes on iOS — critical stability failure for point-of-care tool.
- Upset user base due to new 'free view' limits — high risk of churn to free alternatives.
- Recent updates focused on maintenance rather than feature expansion, while competitors like Figure 1 are innovating in case-based learning.
The SWOT
- Market-leading brand with 2M+ prescribers
- Unique 30-drug interaction checker and visual Pill ID
- Full offline database functionality
- Add evidence-based summaries to calculators to match MDCalc
- Integrate patient education materials to compete with UpToDate
- Develop visual case-sharing features to counter Figure 1
Next best moves
Immediate Hotfix for iOS v26.4.0
+ 2 more prioritized movesFeature gaps
Evidence-based clinical decision rules and PubMed links (available in MDCalc) +3
Since the last report: Epocrates is experiencing a decline in user trust and stability, driven by a shift toward aggressive paywalling and critical performance bugs that are alienating its professional user base.
Bottom line
epocrates remains a revenue powerhouse as the #1 Grossing medical app, but it is currently burning user trust through a combination of critical stability failures and an overly restrictive paywall. To maintain its market lead, the PM must prioritize technical reliability and find a monetization balance that doesn't block the core utility of drug lookups for daily clinical practice.
Unlock 3 critical frictions, 3 market threats, 2 more prioritized moves and the analyst’s take.
Access the full report for freeReport last updated